The Significance of Poly-Targeting in Apoptosis Induction by Alkylating Agents and Platinum Drugs

作者: Jan M. Woynarowski , Barbara A. Woynarowska

DOI: 10.1007/978-1-59745-221-2_22

关键词:

摘要: Apoptosis is believed to be an important aspect of the anticancer potency alkylating agents (AAs) and platinum (Pt) complexes. Despite high clinical utility these classes drugs, nature determinants apoptotic sensitivity/resistance cancer cells are not completely understood. One underappreciated wide variable spectrum cellular targets AAs Pt drugs complexity responses poly-targeted insults. This chapter discusses heterogeneity targeting profiles for diverse drug types interdependence routes elicited by damage various targets. Although many target DNA, DNA only cause their effects. Drugs that alkylate proteins strongly apoptotic, even if they do react with DNA. The ability inactivate specific globally distort state proteome needs considered as a self-standing stimulus factor enhances lethal damage. Particular emphasis placed on significance effects redox-regulating thioredoxin family. Disruption protein redox homeostasis likely critical death/survival in response drugs. Differential distortion regulation suggested molecular basis underlying demonstrated potential such irofulven oxaliplatin promote apoptosis while sparing normal cells.

参考文章(244)
Marcel Horky, Jozefa Wesierska-Gadek, Marieta Gueorguieva, Dual action of cyclin-dependent kinase inhibitors: induction of cell cycle arrest and apoptosis. A comparison of the effects exerted by roscovitine and cisplatin. Polish Journal of Pharmacology. ,vol. 55, pp. 895- 902 ,(2003)
Bernd Kaina, Kirsten Ochs, Sabine Grösch, Gerhard Frizz, Jochen Lips, Maja Tomicic, Torsten Dunkern, Markus Christmann, BER, MGMT, and MMR in defense against alkylation-induced genotoxicity and apoptosis Progress in Nucleic Acid Research and Molecular Biology. ,vol. 68, pp. 41- 54 ,(2001) , 10.1016/S0079-6603(01)68088-7
Michael J. Kelner, Trevor C. McMorris, Rafael J. Rojas, Nicole A. Trani, Tami R. Velasco, Leita A. Estes, Pharnuk Suthipinijtham, Enhanced Antitumor Activity of Irofulven in Combination with Antimitotic Agents Investigational New Drugs. ,vol. 20, pp. 271- 279 ,(2002) , 10.1023/A:1016201807796
Giles Fj, Koeffler Hp, Secondary myelodysplastic syndromes and leukemias. Current Opinion in Hematology. ,vol. 1, pp. 256- 260 ,(1994)
Eman M. Ali Emadi, Kathryn Fay Tonissen, Francis Michael Clarke, David T. Lincoln, The thioredoxin-thioredoxin reductase system: over-expression in human cancer. Anticancer Research. ,vol. 23, pp. 2425- 2433 ,(2003)
Junji Yodoi, Hiroki Nanri, Takefumi Ohga, Mayumi Ono, Akira Yokomizo, Morimasa Wada, Michihiko Kuwano, Kimitoshi Kohno, Yoshinari Makino, Takashi Okamoto, Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide Cancer Research. ,vol. 55, pp. 4293- 4296 ,(1995)
Pendyala L, Creaven Pj, In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Research. ,vol. 53, pp. 5970- 5976 ,(1993)
Reiner U. Jänicke, Quinn L. Deveraux, Stanislaw Krajewski, Alan G. Porter, Rolf Jaggi, Andreas Marti, Céline Blanc, John C. Reed, Caspase-3 is essential for procaspase-9 processing and cisplatin-induced apoptosis of MCF-7 breast cancer cells. Cancer Research. ,vol. 60, pp. 4386- 4390 ,(2000)
S. de Jong, T. Timmer, F.J. Heijenbrok, E.G.E. de Vries, Death receptor ligands, in particular TRAIL, to overcome drug resistance. Cancer and Metastasis Reviews. ,vol. 20, pp. 51- 56 ,(2001) , 10.1023/A:1013112624971